Cas:31384-08-4 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione manufacturer & supplier

Chemical Name:2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione

CAS.NO:31384-08-4

Synonyms:1,2,3,4-Tetrahydro-2,3,6-triaza-naphthalin-1,4-dion;2,3-dihydro-pyrido[3,4-d]pyridazine-1,4-dione;2,3-Dihydro-pyrido[3,4-d]pyridazin-1,4-dion;cinchomeronic acid hydrazide

Molecular Formula:C₇H₅N₃O₂

Molecular Weight:163.13300

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.424g/cm3

Index of Refraction:1.593

PSA:78.61000

Exact Mass:163.03800

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,2,3,4-Tetrahydro-2,3,6-triaza-naphthalin-1,4-dion chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cinchomeronic acid hydrazide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-dihydro-pyrido[3,4-d]pyridazine-1,4-dione Use and application,1,2,3,4-Tetrahydro-2,3,6-triaza-naphthalin-1,4-dion technical grade,usp/ep/jp grade.

Related News: Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday. 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione manufacturer The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione supplier The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione factory  The StartScore model was developed by the company��s in-house supply chain experts based on actual performance data.